Hence, the association of increased AP1M2 expression levels with poor prognosis in BRCA patients may be related to the fact that AP1M2 expression suppresses immunocyte infiltration into tumor microenvironment and decreased immune score. The gene discussed is AP1M2; the disease is neoplasm.